Skip to Content

StageZero Life Sciences Ltd SZLSF Stock Quote

| Rating as of


Market Closed

| Currency in USD

  • Last Close 0.04
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Investment Style Small Blend
  • Day Range 0.04  –  0.04
  • Year Range 0.03  –  0.10
  • Market Cap 4.9578 Mil
  • Volume / Avg 25,011.0 /  3,928.1
  • Price / Sales 1.44
  • Price / Book
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis SZLSF

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics SZLSF

Company Profile SZLSF

Business Description

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.

70 East Beaver Creek Road, Unit 30
Richmond Hill, ON, L4B 3B2, CAN
Industry Diagnostics & Research
Employees 40

Competitors & Peers SZLSF

Morningstar does not cover competitors or peers for this firm.

FAQs for StageZero Life Sciences Ltd Stock

No. SZLSF does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

SZLSF’s market cap is 4.96 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

SZLSF’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

SZLSF’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare SZLSF’s historical performance against its industry peers and the overall market.